Dr. Christopher Cannon talks about the use of JARDIANCE to reduce the risks of cardiovascular death in adults with type 2 diabetes
Guest biography: Dr. Christopher Paul Cannon is a specialist in cardiovascular medicine at Brigham and Women's Hospital (BWH) and professor of medicine at Harvard Medical School (HMS). Dr. Cannon is the executive director of cardiometabolic assays at the Harvard Clinical Research Institute. Dr. Cannon earned his medical degree from the College of Physicians and Surgeons of Columbia University. He completed an internship at the New York-Presbyterian Hospital and a cardiology fellowship at BWH. Dr. Cannon is board certified in internal medicine.
General description of the segment: Dr. Christopher Cannon, analyzes JARDIANCE, a treatment that can help reduce the risk of cardiovascular death in adults with type 2 diabetes and known cardiovascular disease.
For more information about this interview, visit this link:
Video credits to Health Professional Radio YouTube channel